key: cord-0846586-4ol4qh0k authors: Gross, Jane E.; McCown, Michael Y.; Okorie, Caroline U. A.; Bishay, Lara C.; Dy, Fei J.; Astudillo, Carmen Leon; Muhlebach, Marianne S.; Abu-Nassar, Sara; Chen, Diana Y.; Hossain, Nazia; Wang, Ruobing; Klouda, Timothy; Martiniano, Stacey L.; Lenhart-Pendergrass, Patricia; Kirkby, Stephen; Ortenberg, Robin; McSparron, Jakob I.; Wang, Tisha; Hayes, Margaret M.; Çoruh, Başak title: ATS Core Curriculum 2021. Pediatric Pulmonary Medicine: Pulmonary Infections date: 2021-09-08 journal: ATS scholar DOI: 10.34197/ats-scholar.2021-0034re sha: 9a5934c2cff96805f50c0cfb7a17063540e791ed doc_id: 846586 cord_uid: 4ol4qh0k The following is a concise review of the Pediatric Pulmonary Medicine Core reviewing pediatric pulmonary infections, diagnostic assays, and imaging techniques presented at the 2021 American Thoracic Society Core Curriculum. Molecular methods have revolutionized microbiology. We highlight the need to collect appropriate samples for detection of specific pathogens or for panels and understand the limitations of the assays. Considerable progress has been made in imaging modalities for detecting pediatric pulmonary infections. Specifically, lung ultrasound and lung magnetic resonance imaging are promising radiation-free diagnostic tools, with results comparable with their radiation-exposing counterparts, for the evaluation and management of pulmonary infections. Clinicians caring for children with pulmonary disease should ensure that patients at risk for nontuberculous mycobacteria disease are identified and receive appropriate nontuberculous mycobacteria screening, monitoring, and treatment. Children with coronavirus disease (COVID-19) typically present with mild symptoms, but some may develop severe disease. Treatment is mainly supportive care, and most patients make a full recovery. Anticipatory guidance and appropriate counseling from pediatricians on social distancing and diagnostic testing remain vital to curbing the pandemic. The pediatric immunocompromised patient is at risk for invasive and opportunistic pulmonary infections. Prompt recognition of predisposing risk factors, combined with knowledge of clinical characteristics of microbial pathogens, can assist in the diagnosis and treatment of specific bacterial, viral, or fungal diseases. A variety of organisms infect the airways and lung parenchyma, including bacteria, mycobacteria, viruses, and fungi. Diagnostic methods have improved greatly in recent years, yet culture remains the clinical gold standard for bacteria, mycobacteria, and fungi. Disadvantages of culture include a limited spectrum of culturable organisms, the time until results, and personnel efforts. Advantages include quantitative results and the ability to further test the organism. Besides conventional identification of organisms by growth characteristics and biochemical testing, 16S rRNA sequencing and mass spectrometry (matrix-assisted laser desorption ionization-time-of-flight mass spectrometry) have enhanced the sensitivity and accuracy of species-level identification. Culture-independent methods typically rely on amplification of bacterial or viral nucleic acids and subsequent identification (1) . Polymerase chain reaction (PCR) with or without quantitation has been available the longest, and newer, refined methods of nucleic acid extraction and amplification have streamlined the process, including isothermal nucleic acid extraction and amplification for high-throughput and point-of care testing. Several syndromic panels for upper and lower respiratory tract infections are commercially available (2) . These multiplex panels include bacterial, atypical bacterial, and viral codetection, often with concomitant detection of bacterial resistance genes. Sensitivity and specificity vary among panels and specimen types. Sensitivity for different targets may differ within a sample, and detection of bacterial resistance in a mixed infection may not be pathogen specific (3) . Increasingly, panels are semiquantitative to decrease uncertainty about contamination versus a clinically relevant bacterial load. Figure 1 demonstrates standard pathways for respiratory organism identification. Clinicians should understand the appropriate specimen type (swab, induced or expectorated sputum, bronchoalveolar lavage fluid) relevant to the clinical question and recognize that sample quality and contamination are a few of the issues that may affect interpretation, especially for molecular diagnostics (4) . Viral detection is largely PCR-based, with many point-of-care methods for single or multiplex detection being available. Separate panels are optimized and Food and Drug Administration-approved for upper and lower respiratory tract samples. Antigenbased viral detection is widely used (e.g., influenza, severe acute respiratory syndrome coronavirus 2 [SARS-CoV-2]) and has rapid results but lower performance. Correspondence and requests for reprints should be addressed to Jane E. Gross, M.D., Ph.D., National Jewish Health, 1400 Jackson Street, J329, Denver, CO 80206. E-mail: grossjane@njhealth.org. Fungal diagnostics are often used in immunocompromised patients (ICPs). Culture and histopathology of secretions or tissues with fungus-specific staining remain valuable. Molecular methods include panfungal PCR and pathogen-specific PCR. Some syndromic lower respiratory infection panels include targets for Aspergillus fumigatus, Pneumocystis jirovecii, and Cryptococcus neoformans (5) . To date, there are few published evaluations of those tests. Antigen detection assays are available for Cryptococcus, Aspergillus (galactomannan), Candida (enolase), and b-glycan as nonspecific markers of fungal infection. Given the concern of contamination from upper airway secretions, evaluation of the host's immune response to fungus can provide specificity. Assays include complementfixation, immunodiffusion, and enzyme immune assays. Diagnosis of mycobacterial infections remains challenging, given the fastidious nature of the organisms. Culture remains the gold standard, followed by Mycobacterium tuberculosis-specific PCR (6) . Skin and serologic tests are routinely used for tuberculosis, with cautious interpretation being used for ICPs. For nontuberculous mycobacteria (NTM), culture remains the standard in most settings; however, molecular assays and panmycobacterial PCR with gene sequencing for subtype identification are becoming available (7) . In addition to clinical assessment and microbial tests, imaging studies can aid in the diagnosis and management of pulmonary infections. Although plain chest radiography (CXR) is often the preferred initial modality, findings are often normal or nonspecific. Chest computed tomography (CT) remains the gold standard for characterization of pulmonary infections but increases the totaldose radiation exposure. Lung ultrasound (LUS) and lung magnetic resonance imaging (MRI) have gained attention as radiation-free alternatives for pulmonary imaging. Video 1 shows common radiologic findings for pulmonary infections from the imaging modalities described in this review. Although the diagnosis of pneumonia is made in a clinical context, CXR studies are often obtained, although appreciable falsenegative rates and wide inter-and intraobserver interpretation variability are reported. LUS is an advantageous alternative diagnostic modality that can detect the presence of consolidations, focal B-lines, pleural line abnormalities, and effusions with significantly better sensitivity than (95.5% vs. 86.8%) and specificity similar to (95.3% vs. 98.2%) CXR alone or in combination with clinical findings, and the use of LUS results in less interpretation variability (1, 2) . LUS is better for diagnosing and characterizing pleural effusions and identifying mediastinal lymphadenopathy in suspected pulmonary tuberculosis than CXR (3, 4) . LUS techniques yield quality imaging results in children because of their unique anatomical features, including a thinner chest wall and smaller thoracic width. Advantages to LUS include the lack of radiation exposure, lower relative cost, potential for expanded access in low-resource settings, and rapid availability of results (5). CT is the gold standard for detecting pulmonary infection and for diagnosing bronchiectasis and air trapping. Despite routine use of pediatric low-dose CT protocols, minimizing the cumulative dose of radiation exposure in children remains crucial, particularly in patients with DNA-repairing deficiencies and oncologic conditions. With advances in imaging quality, emerging studies have aimed to validate MRI as a radiationfree alternative. The advancements and development of MRI with fast-imaging sequences and higher field strengths have enhanced image resolution while reducing total scan times and the need for prolonged sedation (6 NTM are ubiquitous in the environment, particularly in soil and water sources. They can cause uncommon, but significant, pulmonary disease in children (1, 2) . These atypical pathogens are slow growing compared with typical bacteria and require special culture conditions for proper isolation and identification (3). NTM species associated with pulmonary disease in children include the M. abscessus group (MAB) (which includes the subspecies abscessus, massiliense, and bolletii), which typically grow within 1 week in culture, as well as slower growing species such as M. avium complex (MAC) (which includes M. avium, M. intracellulare, and M. chimaera, among others) and M. kansasii, which can take weeks to grow in culture (4). In the pediatric population, NTM infections most commonly occur in children with CF. Pulmonary NTM can also be diagnosed in children with non-CF bronchiectasis, including primary ciliary dyskinesia, autosomal dominant hyper-IgE syndrome, and primary or secondary immunodeficiencies (5) . MAC and MAB are the most common species associated with pulmonary disease in the United States. Annual screening for NTM should be performed in older children with CF via an expectorated or induced sputum culture, even if they are asymptomatic. Routine screening should also be considered in children with non-CF bronchiectasis. In addition, the presence of NTM should be considered in pulmonary infections or exacerbations that are unresponsive to treatment of typical pathogens or that present with an unexpected clinical decline. Because NTM can cause transient or indolent infection, or be a contaminant, it is imperative that careful consideration of the cause and a formal diagnosis of NTM pulmonary disease is made before starting treatment. Diagnostic criteria are shown in Figure 2 . If a patient is on chronic azithromycin therapy for immunomodulation, it should be stopped upon isolating NTM to avoid partial treatment and induced resistance. Management of NTM disease in children requires a prolonged course of multiple antibiotics, with the treatment choice being based on the species or subspecies and guided by susceptibilities. Expert consultation is recommended, especially for drug-resistant MAC or MAB (4). Standard treatment approaches are shown in Table 1 for the most common NTM (4, 6) . Newer antibiotics that show in vitro activity against NTM are included on the basis of updated treatment guidelines (6) . Typically, MAC and M. kansasii can be treated with an oral antibiotic regimen. MAB requires an intensive phase of intravenous and oral antibiotics, which is followed by a continuation phase of oral and inhaled antibiotics. Daily treatment is recommended in children (vs. thrice-weekly treatment in adults) because of drug metabolism. Any patient started on NTM treatment requires frequent follow-up with intensive drug-toxicity monitoring (e.g., audiograms, vision testing, electrocardiography, and laboratory testing). The goal of treatment is to achieve 12 months of consecutive negative culture results. If microbiologic conversion cannot be achieved, drug concentrations should be measured and alternate antibiotics can be trialed. (2). The SARS-CoV-2 virus gains entry into cells by binding to the ACE2 receptor (3) . The reason children experience less severe symptoms is unknown, and hypotheses include children having lower levels of ACE2, differential immune responses, and fewer comorbidities (4). To date, only age (less than 1 yr old) and having a preexisting medical condition have been identified as risk factors for severe disease in children (5) . Children typically have mild symptoms and a fast recovery, with 17.4-19.3% of children with COVID-19 being asymptomatic (6, 7) . The incubation period is estimated to be 2-14 days, and symptomatic patients typically recover in 2-4 weeks (8) . Common symptoms include fever (51.2-59.1%), cough (37.0-55.9%), rhinorrhea (9.9-20.0%), and pharyngitis (8.3-18.2%) (6, 7) . Diagnosis of COVID-19 is typically through detection of viral mRNA from a respiratory sample with reverse transcription-PCR. The accuracy of testing results depends on numerous factors, such as the sample source and the viral load present. Consultation with an infectious disease expert is recommended in certain clinical scenarios (e.g., congenital or acquired immunodeficiency) to ensure proper test interpretation and determine the need for possible retesting (8) . Although laboratory findings have limited diagnostic and prognostic value, lymphopenia as well as elevated creatinine kinase, liver enzymes, and procalcitonin have been documented (7). CT abnormalities can present before clinical symptoms and may include GGOs and consolidations (6, 7) . Currently, there are no specific therapies for children with COVID-19. Stable patients are advised to quarantine at home (8) . Treatment strategies for hospitalized patients include supplemental oxygen, fluid resuscitation, and empiric antibiotics when indicated (8) . Systemic corticosteroids are not recommended. Patients in whom supplemental oxygen fails should be escalated to noninvasive positive pressure ventilation before mechanical ventilation with lung-protective strategies (9) . Monoclonal antibodies to SARS-CoV-2 can be administered to high-risk pediatric patients 12 years or older who test positive for SARS-CoV-2 (10). To date, the Pzifer-BioNTech COVID-19 mRNA vaccine is the only vaccine available to patients 12 years or older. Clinical trials for patients under 12 years of age are currently ongoing. An estimated 13.3% of pediatric patients with COVID-19 are admitted to the hospital, with 3.5% requiring intensive care unit (ICU) care. Mortality is low and is estimated to be less than 1% (5) . Multisystemic inflammatory syndrome in children is a rare complication defined by fever, systemic inflammation, and multiorgan dysfunction seen after COVID-19 infection in patients 3-12 years old. There are no established guidelines, and treatment includes intravenous immunoglobulin and glucocorticoids. With multisystemic inflammatory syndrome in children, 80% of patients require ICU care, and mortality is estimated at 2% (11) . The pediatric ICP is at risk for invasive and opportunistic pulmonary infections. Prompt recognition of predisposing risk factors, combined with knowledge of clinical characteristics of microbial pathogens, can assist in the diagnosis and treatment of specific bacterial, viral, or fungal diseases. There are hundreds of primary immunodeficiencies, further characterized by specific cellular defects (1). Disorders affecting T cells are likely to present with recurrent or severe viral and fungal infections. B-cell abnormalities lead to decreased antibody production and recurrent bacterial pneumonias, specifically caused by encapsulated organisms (2) . Secondary immunodeficiencies vary in severity depending on the underlying cause of disease and include diabetes, malignancy, malnutrition, sickle-cell disease, human immunodeficiency virus, and immunomodulatory medication use. In addition, significant immunosuppressive states exist related to solid organ or bone marrow transplantation (3). Evaluation of the ICP with respiratory symptoms should aim to quickly identify the source organism and rule out noninfectious etiologies. Imaging with CXR or CT can assist in identifying pathognomonic patterns of disease, in conjunction with specific laboratory studies. Bronchoscopy with bronchoalveolar lavage remains a key tool for diagnosis through cultures, cytology, and molecular diagnostic testing (such as PCR) (4) . There may also be a limited role for lung biopsy (transbronchial or radiology-guided biopsy) or sampling of other tissues, such as lymph nodes or skin (Table 2) . Infectious disease consultants can offer valuable assistance in specific testing, particularly in complicated cases. Bacterial infections are commonly encountered among ICPs and may be acquired in the community or healthcare setting. Clinicians should have high clinical suspicion and quickly institute appropriate broad antibiotic coverage for gram-positive and gram-negative species, as the typical treatment for community-acquired pneumonia in immunocompetent hosts may be insufficient (5) . Slow-growing bacterial species including mycobacteria and Nocardia species may also be identified in ICPs. Practitioners can tailor treatment to a specific pathogen once cultures and drug susceptibility patterns are identified. Although many fungi represent commensal or nonpathologic organisms, others can cause true infection in the ICP. P. jirovecii is a common infection among organ transplant recipients as well as patients with chronic systemic glucocorticoid therapy or prolonged neutropenia or lymphopenia. Prophylactic strategies are often used in these high-risk patients. Aspergillus species, including A. fumigatus, may cause invasive pulmonary aspergillosis with sequelae such as necrotizing pneumonia, vascular invasion, and hematologic spread. These patients may present with hemoptysis or pulmonary infarction. The classic radiologic finding in invasive pulmonary aspergillosis is a cavitary lesion with surrounding GGO, the so-called "halo sign." The highest-risk patients include those with hematologic malignancies and bone marrow transplant recipients. Other important fungal pathogens to consider in ICPs include mucormycosis, cryptococcosis, and Candida infections. Published guidelines detail the diagnosis of pulmonary fungal infections (6) . Seasonal community-acquired viral infections, including with influenza, respiratory syncytial virus, adenovirus, and other common upper respiratory tract viruses, are more likely to cause clinical pneumonia in pediatric ICPs. A high level of suspicion and prompt diagnostic testing via PCR panels are indicated. Solid organ and bone marrow transplant recipients are at particularly high risk for cytomegalovirus, which can cause pneumonitis and other organ disease. Risk is based in part on the seropositivity of the donor and recipient, and prophylactic strategies are often employed (7) . Molecular approaches to studying microbial communities: targeting the 16S ribosomal RNA gene Rapid syndromic molecular testing in pneumonia: the current landscape and future potential Evaluation of a novel multiplex PCR Panel compared to quantitative bacterial culture for diagnosis of lower respiratory tract infections Molecular testing for acute respiratory tract infections: clinical and diagnostic recommendations from the IDSA's Diagnostics Committee A new age in molecular diagnostics for invasive fungal disease: are we ready? Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children Added diagnostic value of 16S rRNA gene pan-mycobacterial PCR for nontuberculous mycobacterial infections: a 10-year retrospective study Lung ultrasound compared to chest X-ray for diagnosis of pediatric pneumonia: a meta-analysis Lung ultrasound for the diagnosis of community-acquired pneumonia in children Chest imaging in paediatric pulmonary TB Chest ultrasound compared to chest X-ray for pediatric pulmonary tuberculosis Ultrasound diagnosis of pneumonia in children Rapid lung MRI in children with pulmonary infections: time to change our diagnostic algorithms Magnetic resonance imaging of pulmonary infection in immunocompromised children: comparison with multidetector computed tomography Validating chest MRI to detect and monitor cystic fibrosis lung disease in a pediatric cohort The clinical use of lung MRI in cystic fibrosis: what, now, how? Opportunistic pathogens enriched in showerhead biofilms Nontuberculous mycobacterial infections in cystic fibrosis The Nontuberculous Mycobacteria in Cystic Fibrosis Study Group. Proficiency testing of clinical microbiology laboratories using modified decontamination procedures for detection of nontuberculous mycobacteria in sputum samples from cystic fibrosis patients Infectious Disease Society of America. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Nontuberculous mycobacterial infections in children Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS/ERS/ESCMID/IDSA clinical practice guideline Demographic trends of COVID-19 cases and deaths in the US reported to CDC COVID-19: impacts and implications for pediatric practice A pneumonia outbreak associated with a new coronavirus of probable bat origin Why is COVID-19 less severe in children? A review of the proposed mechanisms underlying the age-related difference in severity of SARS-CoV-2 infections COVID-19 WORKING GROUP. COVID-19 disease severity risk factors for pediatric patients in Italy COVID-19 in 7780 pediatric patients: a systematic review Clinical characteristics of children with COVID-19: a meta-analysis Diagnosis and treatment recommendations for pediatric respiratory infection caused by the 2019 novel coronavirus European consensus recommendations for neonatal and paediatric retrievals of positive or suspected COVID-19 patients Monoclonal antibodies to disrupt progression of early COVID-19 infection Overcoming COVID-19 Investigators; CDC COVID-19 Response Team. Multisystem inflammatory syndrome in U.S. children and adolescents Pulmonary manifestations of primary immunodeficiency disorders in children Immunodeficiency disorders Fiberoptic bronchoscopy and bronchoalveolar lavage for the evaluation of pulmonary disease in children with primary immunodeficiency and cancer Nine-i Investigators. Diagnosis of severe respiratory infections in immunocompromised patients Microbiological laboratory testing in the diagnosis of fungal infections in pulmonary and critical care practice: an official American Thoracic Society clinical practice guideline Prevention and treatment of cytomegalovirus infection in solid organ transplant recipients Author disclosures are available with the text of this article at www.atsjournals.org.